<img alt="" src="https://secure.lote1otto.com/219869.png" style="display:none;">

Cytel Inc. Congratulates Lipopharma and CLINGLIO Consortium on Recent Grant Award

Amazing Flag of European Union.jpeg

Cambridge, MA, USA 27th February 2018 Cytel Inc., a global provider of innovative analytical software and services to the biopharmaceutical industry, congratulates Lipopharma and the CLINGLIO project consortium on their recent 6,15M€ grant award by the European Union’s Horizon 2020 program. Led by Lipopharma, the multinational consortium brings together 12 academic and industry organizations from Europe, Israel, and the USA.

The group will use the award to execute the project “A Clinical Phase IIB trial with 2OHOA in patients with newly-diagnosed malignant glioma”. The double-blind, randomized adaptive trial will assess the efficacy and safety of 2OHOA in combination with radiotherapy and temozolomide in primary newly diagnosed glioblastoma patients and compare Progression Free Survival (PFS) between 3 treatment groups in 2 stages.

Cytel collaborated with Lipopharma and the consortium to create the innovative trial design and provided statistical input for the successful grant application. The design uses an interim analysis to determine the best dose and final sample size, while simultaneously investigating the molecular basis of patient subpopulations more likely to respond to 2OHOA treatment. It incorporates interim dose selection, sample size reassessment and biomarker threshold/omics signature determination features to achieve the trial’s objectives while assuring its integrity.

Lingyun Liu, Associate Director of Strategic Consulting at Cytel, said, "By combining dose optimization, sub-population detection, and biomarker determination objectives in a single study, this design makes the best use of available clinical data and effectively streamlines the development pathway.”

Yannis Jemiai, Senior Vice President at Cytel, added, “We are delighted that the CLINGLIO project has been awarded a Horizon 2020 grant to take this important trial forward. Glioma has an extremely poor prognosis and new, effective therapies are urgently required. Our team is proud to use its biostatistics expertise to help address the pressing unmet needs in this disease area. ”

To learn more about the trial, which will recruit participants at sites in Europe and Israel, visit www.lipopharma.com.

Connect with Cytel

Meet at ASCO 2018 Cytel is attending the ASCO Conference June 1st to 5th and will be available to discuss adaptive trial strategies for oncology development. Visit the team at Booth #20101.

Read our blog The Cytel Blog

Follow us on Twitter @cytel

Engage with us on LinkedIn

About Cytel

Cytel is shaping the future of drug development. As the world's largest independent biostatistics clinical research organization (CRO), and pioneer in adaptive trials, Cytel helps leading pharmaceutical, biotech, and medical device companies improve clinical success rates via optimal study design, effective data management, and accurate statistical analysis. Cytel provides both software solutions for the design and analysis of clinical trials, including industry standards East®, StatXact® and LogXact®, as well as data-focused clinical research services. With operations across North America, Europe, and India, Cytel employs 900 professionals, with strong talent in biostatistics, programming, and data management. For more information on Cytel, visit http://www.cytel.com/.

Cytel Contact

Liz Cole
Director, Marketing Communications